Bevacizumab reduces tumor targeting of antiepidermal growth factor and anti‐insulin‐like growth factor 1 receptor antibodies

Sandra Heskamp(Radboud University Nijmegen), Hanneke W.M. van Laarhoven(Dutch Cancer Society)

International Journal of Cancer

January 21, 2013

10.1002/ijc.28046

Cited by 55

Related Papers

Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours (LEOPARD-2): a multicentre, patient-blinded, randomised controlled phase 2/3 trial

|The Lancet. Gastroenterology & hepatology|2019|597

White blood cell and cell-free DNA analyses for detection of residual disease in gastric cancer

|Nature Communications|2020|238

Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6)

|BMC Cancer|2019|111

ImmunoSPECT and ImmunoPET of IGF-1R Expression with the Radiolabeled Antibody R1507 in a Triple-Negative Breast Cancer Model

|Journal of Nuclear Medicine|2010|92

Supervised exercise after oesophageal cancer surgery: the PERFECT multicentre randomized clinical trial

|British journal of surgery|2021|42